Teva to Present at the 30th Annual J.P. Morgan Healthcare Conference

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the J.P. Morgan Healthcare Conference in San Francisco, CA. Eyal Desheh, Chief Financial Officer, and William Marth, President & CEO, Teva Pharmaceuticals – Americas, will present on Tuesday, January 10, 2012.

What: Teva Presentation at the 30th Annual J.P. Morgan Healthcare Conference

Who: Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd. &

William Marth, President and CEO, Teva Pharmaceuticals - Americas

When: Tuesday, January 10, 2012 at 9:30 a.m. (PST)

Where: http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-presentations or
http://jpmorgan.metameetings.com/webcasts/healthcare12/directlink?ticker=TEVA

How: Live over the Internet – log on to the Web at the address above and register for the event (approximately 10 minutes before). An archive of the webcast will be available on Teva’s website.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 47,000 people around the world and reached $16.1 billion in net sales in 2010.



CONTACT:

IR:
Teva Pharmaceutical Industries Ltd.
Elana Holzman, 972 (3) 926-7554
or
Teva North America
Kevin C. Mannix, (215) 591-8912
or
PR:
Teva Pharmaceutical Industries Ltd.
Yossi Koren, 972 (3) 926-7687
or
Teva North America
Denise Bradley, (215) 591-8974

KEYWORDS:   United States  North America  California  Pennsylvania  Middle East  Israel

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Other Health

MEDIA:

Suggested Articles

Merck & Co. set out to answer the question of whether lung cancer patients with KRAS mutations respond as well to Keytruda as others do.

Merck and Roche are no strangers to sparring with their I-O meds Keytruda and Tecentriq, but in TNBC, Keytruda's latest data take the prize.

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.